HK Stock Market Move | ROBOTPHOENIX(06871) has risen by over 17% again, accumulating more than 80% in the past three days. Recently, they teamed up with Siemens to appear at the LET2026 Guangzhou Logistics Exhibition.
Wingtech Technology (06871) surged over 17% again, with a cumulative increase of over 80% in the past three trading days. As of the time of writing, it has risen 13.4% to 34.02 Hong Kong dollars, with a trading volume of 1.13 billion Hong Kong dollars.
ROBOTPHOENIX (06871) has risen by more than 17%, with a cumulative increase of over 80% in the past three trading days. As of the announcement, it has risen by 13.4%, reaching 34.02 Hong Kong dollars, with a turnover of 1.13 billion Hong Kong dollars.
On the news front, the 2026 International Logistics Equipment Exhibition was recently held in Guangzhou. As a core ecosystem partner of Siemens Xcelerator, ROBOTPHOENIX debuted at booth D37 in Siemens Hall 20.1, showcasing a new generation of fully open mold-wheeled humanoid platform - dual-mode four-wheel drive and omnidirectional intelligent chassis. The product is compatible with Siemens S7-1200G2 controller, integrating mature industrial control ecosystem and self-developed chassis technology to demonstrate new solutions for warehousing and handling under the integration of physical and digital spaces.
Public information shows that ROBOTPHOENIX specializes in industrial Siasun Robot & Automation solutions for the entire light industry product category, building a matrix of parallel, SCARA, wafer, six-axis, and mobile Siasun Robot & Automation, supported by self-developed control and vision systems, covering consumer electronics, automotive parts, new energy, medical and health scenes, and is one of the few domestic companies with the ability to cover the entire Siasun Robot & Automation product category.
Related Articles

Tasly Pharmaceutical Group's subsidiary has obtained the registration certificate for bosentan dispersible tablets.

Huiyu Pharmaceutical (688553.SH) subsidiary's clinical trial application for injection HY07121 (subcutaneous injection) has been accepted.

Hangzhou Haoyue Personal Care (605009.SH) plans to invest up to 20 million US dollars to establish an overseas subsidiary in Egypt and build a production base.
Tasly Pharmaceutical Group's subsidiary has obtained the registration certificate for bosentan dispersible tablets.

Huiyu Pharmaceutical (688553.SH) subsidiary's clinical trial application for injection HY07121 (subcutaneous injection) has been accepted.

Hangzhou Haoyue Personal Care (605009.SH) plans to invest up to 20 million US dollars to establish an overseas subsidiary in Egypt and build a production base.

RECOMMEND





